JPRN-jRCT2080221712未知2 期
A dose-finding phase II study of TAS-108
适应症
试验速览
- 阶段
- 2 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- Female
入选标准
- •(1) Have a cytologically or histologically confirmed breast cancer as the primary lesion
- •(2) Postmenopausal women 20 to 80 years of age who meet one of the following conditions:
- •1) Women 50 years of age or older and amenorrheic for at least 12 months
- •2) Women less than 50 years of age, amenorrheic for at least 12 months, and with both serum estradiol-17 beta (E2) and follicle-stimulating hormone (FSH) levels in the postmenopausal range of each institution* (patients with luteinizing hormone-releasing hormone (LH-RH) agonist-induced menopause will be excluded from this study)
- •3) Women less than 50 years of age, amenorrheic for at least 3 months by irradiation, and with both serum E2 and FSH levels in the postmenopausal range of each institution*
- •*E2 and FSH tests are not required in patients who have undergone bilateral oophorectomy.
- •(3) Have estrogen receptor (ER)-positive or progesterone receptor (PgR)-positive breast cancer
- •(4) Have at least one measurable lesion the size of which has been measured within 4 weeks prior to enrollment
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A study of TAS-120 in patients with advanced cancer with or without genetic abnormalitiesAdvanced solid tumors and multiple myelomaMedDRA version: 16.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864MedDRA version: 16.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2013-004810-16-ESTaiho Pharma USA, Inc.835
已完成
1 期
A phase I/II trial of TAS-102 in combination with irinotecan in Japanese patients with advanced gastric cancer refractory to standard chemotherapiesadvanced gastric cancer refractory to standard chemotherapiesJPRN-UMIN000031346St. Marianna University School of Medicine11
已完成
2 期
Randomized phase II study of dose schedule of TS-1 for resected Colorectal CancerStage III colorectal cancerJPRN-UMIN000013185Clinical Study Group of Osaka (CSGO), Colorectal Cancer Treatment Group170
招募中
不适用
A PhaseII Study of Dose Schedule of TS-1 for Metastatic/Advanced Breast CancerMetastatic/Advanced Breast CancerJPRN-UMIN000008879Wakayama Medical University, Department of Thoracic and Cardiovascular Surgery40
已完成
2 期
A phase II trial of TAS-102 in combination with cetuximab for patients with RAS wild-type metastatic colorectal cancer refractory to previous anti-EGFR antibodies(WJOG8916G)Metastatic RAS wild type colorectal cancer which has become refractory or there was intolerance to chemotherapies (fluoropyrimidine, irinotecan, oxaliplatin) and bevacizumab, and refractory to anti-epidermal growth factor receptor(EGFR) antibodiesJPRN-UMIN000027210West Japan Oncology Group55